News | Antiplatelet and Anticoagulation Therapies | January 11, 2017

Medication Adherence a Problem in Atrial Fibrillation Patients

University of Michigan study finds nearly 37 percent of subjects were off warfarin therapy within one year of starting; follow-up research needed to assess why

atrial fibrillation patients, warfarin therapy, medication adherence, University of Michigan study, JAMA Cardiology

January 11, 2017 — For patients with atrial fibrillation, the most common form of heart arrhythmia, a main goal of treatment is stroke prevention. As a result, most Afib patients are prescribed a blood thinner such as warfarin, also known by the brand name Coumadin, to combat the potential for blood clots that could lead to stroke. But warfarin is tough to manage, and some patients have trouble adhering to any medication. A new research letter published in JAMA Cardiology finds Afib patients are even more likely to discontinue warfarin therapy if they’ve had a recent procedure done to address their arrhythmia.1

“We don’t know if changing the heart to a normal rhythm, by either cardioversion or ablation, always removes the risk of stroke,” said Geoffrey Barnes, M.D., M.Sc., one of the University of Michigan researchers and a cardiologist at the U-M Frankel Cardiovascular Center. “It’s an ongoing debate, whether to continue the patient on blood thinners after a procedure.”

Researchers from U-M and other institutions that are part of the Michigan Anticoagulation Quality Improvement Initiative analyzed 734 Afib patients across the state who started warfarin therapy between 2011 and 2013.

The researchers found 36.8 percent of subjects were off warfarin within one year of starting it.

“When we took into account whether the patient had undergone a recent Afib procedure, the numbers look very different,” said James Froehlich, M.D., M.P.H., also a researcher with the collaborative and a Frankel center cardiologist. “This may or may not be good news, because when someone’s had a recent procedure, there may be good reason to interrupt anticoagulant therapy.”

When either electrical cardioversion or radiofrequency ablation was performed, more than half of subjects (54.1 percent) were not on warfarin after a year. Electrical cardioversion shocks the heart back into a regular rhythm. Radiofrequency ablation scars the damaged parts of the heart to prevent the dangerous rhythm.

Subjects who did not undergo an Afib procedure were much more likely to continue warfarin therapy, with less than one-third (29.5 percent) discontinuing it.

Although the numbers are much higher for those who underwent a procedure, 29.5 percent is still a sizable proportion of Afib patients discontinuing warfarin therapy, Barnes said. Reasons may vary, from advice from a physician to side effects such as bruising or a patient’s desire to avoid having blood drawn.

“We need to understand why they are stopping warfarin and figure out what other medications might be better adhered to in order to prevent strokes,” Froehlich said.

“Once someone has Afib, we don’t yet know when it is safe to stop anticoagulation therapy,” Froehlich said.

Yet every day, cardiologists must make recommendations to their patients with the condition.

“We need more data to help us understand what the risk of stroke is after cardioversion or ablation, to inform physician decision-making and guidelines,” Barnes said.

In the past couple of decades, it was typical to stop anticoagulants after a patient underwent cardioversion, Froehlich said, but new data are needed — along with more data about ablation.

The facts from the anticoagulation collaborative allowed the researchers to identify practice patterns statewide, working toward improving the care of patients across Michigan who are taking anticoagulants.

The Michigan Anticoagulation Quality Improvement Initiative is funded by Blue Cross Blue Shield of Michigan.

For more information:


1. Barnes, G.D., Kaatz, S., Lopez, A., et al. "Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation," JAMA Cardiology. Published online Jan. 4, 2017. doi:10.1001/jamacardio.2016.5041

Related Content

The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiolo
Xarelto Reduces Ischemic Stroke for Coronary and Peripheral Artery Disease Patients
News | Antiplatelet and Anticoagulation Therapies | February 19, 2018
A late-breaking analysis of the landmark COMPASS study was presented at the 2018 International Stroke Conference (ISC...
Abbott Begins Enrollment in XIENCE 28 GLOBAL DAPT Trial
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018
Abbott announced the first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet...
Baxter Announces FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
Technology | Antiplatelet and Anticoagulation Therapies | January 22, 2018
January 22, 2018 — Baxter International Inc. announced the U.S.
News | Antiplatelet and Anticoagulation Therapies | January 19, 2018
The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is voluntarily recalling Lot...
New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies | December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
News | Antiplatelet and Anticoagulation Therapies | November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
Six Months of DAPT Non-Inferior to Twelve in STEMI Patients Receiving Drug-Eluting Stents
News | Antiplatelet and Anticoagulation Therapies | November 06, 2017
November 6, 2017 —  The first trial to evaluate the safety of...
Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients
News | Antiplatelet and Anticoagulation Therapies | November 03, 2017
November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests...
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies | September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Overlay Init